ZA201103813B - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto - Google Patents
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related theretoInfo
- Publication number
- ZA201103813B ZA201103813B ZA2011/03813A ZA201103813A ZA201103813B ZA 201103813 B ZA201103813 B ZA 201103813B ZA 2011/03813 A ZA2011/03813 A ZA 2011/03813A ZA 201103813 A ZA201103813 A ZA 201103813A ZA 201103813 B ZA201103813 B ZA 201103813B
- Authority
- ZA
- South Africa
- Prior art keywords
- prostacyclin
- modulators
- treatment
- acid derivatives
- carbonic acid
- Prior art date
Links
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 229960001123 epoprostenol Drugs 0.000 title 1
- 125000003226 pyrazolyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20039308P | 2008-11-26 | 2008-11-26 | |
| PCT/US2009/006251 WO2010068242A1 (en) | 2008-11-26 | 2009-11-24 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201103813B true ZA201103813B (en) | 2012-10-31 |
Family
ID=41718771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2011/03813A ZA201103813B (en) | 2008-11-26 | 2011-05-24 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20110224262A1 (OSRAM) |
| EP (2) | EP3342767B1 (OSRAM) |
| JP (1) | JP5603343B2 (OSRAM) |
| KR (1) | KR101707247B1 (OSRAM) |
| CN (1) | CN102292321B (OSRAM) |
| AU (1) | AU2009325117C1 (OSRAM) |
| BR (1) | BRPI0921369B8 (OSRAM) |
| CA (1) | CA2744124C (OSRAM) |
| EA (1) | EA022799B1 (OSRAM) |
| IL (1) | IL212966A (OSRAM) |
| MX (1) | MX2011005577A (OSRAM) |
| NZ (1) | NZ593002A (OSRAM) |
| SG (1) | SG171413A1 (OSRAM) |
| WO (1) | WO2010068242A1 (OSRAM) |
| ZA (1) | ZA201103813B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009117095A1 (en) * | 2008-03-18 | 2009-09-24 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| NZ593002A (en) | 2008-11-26 | 2013-08-30 | Arena Pharm Inc | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| US8940891B2 (en) * | 2008-12-08 | 2015-01-27 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| JP6438199B2 (ja) | 2011-09-30 | 2018-12-12 | 三菱ケミカル株式会社 | 重合性無機粒子分散剤、該重合性無機粒子分散剤を含む無機有機複合粒子、および無機有機樹脂複合材 |
| PL2763993T3 (pl) | 2011-10-06 | 2017-09-29 | Bayer Intellectual Property Gmbh | Heterocyklilopiry(mi)dynylopirazol |
| EP2763987B1 (en) | 2011-10-06 | 2018-07-18 | Bayer CropScience AG | Heterocyclylpyri(mi)dinylpyrazole as fungicidals |
| US10537546B2 (en) | 2014-10-23 | 2020-01-21 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the PGI2 receptor |
| KR20240068077A (ko) | 2016-11-10 | 2024-05-17 | 아레나 파마슈티칼스, 인크. | 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 |
| WO2018160882A1 (en) * | 2017-03-01 | 2018-09-07 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| EP3750879A1 (en) * | 2018-02-07 | 2020-12-16 | Medshine Discovery Inc. | Prostacyclin receptor agonist |
| US12433865B2 (en) | 2018-05-16 | 2025-10-07 | Arena Pharmaceuticals, Inc. | Compositions comprising PGI2-receptor agonists and processes for the preparation thereof |
| CN118922402A (zh) | 2022-02-15 | 2024-11-08 | 联合治疗公司 | 结晶前列环素(ip)受体激动剂及其用途 |
| AU2023338217A1 (en) | 2022-09-09 | 2025-04-03 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021451A (en) | 1911-04-22 | 1912-03-26 | James F Craven | Receptacle for containing and discharging semisolid and pasty substances. |
| DE2945530A1 (de) | 1979-11-10 | 1981-06-04 | Chemische Werke Hüls AG, 4370 Marl | Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide |
| JPH03160438A (ja) | 1989-11-20 | 1991-07-10 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| CA2036192A1 (en) | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
| CA2085844A1 (en) * | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
| JPH06329598A (ja) | 1993-05-19 | 1994-11-29 | Daicel Chem Ind Ltd | エステルの製造方法 |
| DE4318889A1 (de) | 1993-06-07 | 1994-12-08 | Bayer Ag | Verfahren zur Herstellung von organischen Carbamaten |
| JP3160438B2 (ja) | 1993-09-29 | 2001-04-25 | 株式会社東芝 | 交通流予測装置 |
| JPH11269138A (ja) | 1998-03-20 | 1999-10-05 | Mitsubishi Paper Mills Ltd | 有機塩基発生剤 |
| GB9908934D0 (en) * | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| US20040048844A1 (en) * | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| WO2002055484A1 (en) | 2001-01-12 | 2002-07-18 | Takeda Chemical Industries, Ltd. | Biaryl compound, process for producing the same, and agent |
| WO2003007888A2 (en) * | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| RU2315746C2 (ru) * | 2001-08-09 | 2008-01-27 | Оно Фармасьютикал Ко., Лтд. | Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TWI293715B (en) * | 2002-10-10 | 2008-02-21 | Sipix Imaging Inc | A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display |
| WO2004072038A1 (en) * | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| JP4402413B2 (ja) | 2003-09-29 | 2010-01-20 | 財団法人２１あおもり産業総合支援センター | Ｕ字型化合物およびこれを含む液晶組成物 |
| DE102004006785A1 (de) | 2004-02-11 | 2005-09-08 | Mayr, Herbert, Prof. Dr. | Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure |
| WO2006023844A2 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| CN101072564A (zh) * | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
| JP2006083085A (ja) | 2004-09-15 | 2006-03-30 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体の製造法およびその合成中間体 |
| JP4792731B2 (ja) | 2004-11-12 | 2011-10-12 | Ｄｉｃ株式会社 | 重合性液晶組成物及び当該組成物の硬化物 |
| WO2007051255A1 (en) | 2005-11-04 | 2007-05-10 | The University Of Sydney | Process for the preparation of compounds containing an azacyclic ring system |
| JP2007161867A (ja) | 2005-12-14 | 2007-06-28 | Toyo Ink Mfg Co Ltd | インキ組成物 |
| GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| EA200802213A1 (ru) | 2006-05-09 | 2009-10-30 | Химекуэст Фармасьютикалз, Инк. | Способы лечения заболеваний крови |
| WO2009117095A1 (en) * | 2008-03-18 | 2009-09-24 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| NZ593002A (en) | 2008-11-26 | 2013-08-30 | Arena Pharm Inc | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| US8940891B2 (en) * | 2008-12-08 | 2015-01-27 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| EP2480526A1 (en) | 2009-09-23 | 2012-08-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| JP7343478B2 (ja) | 2017-08-07 | 2023-09-12 | アレーナ ファーマシューティカルズ，インク． | 処置の方法 |
-
2009
- 2009-11-24 NZ NZ593002A patent/NZ593002A/xx unknown
- 2009-11-24 BR BRPI0921369A patent/BRPI0921369B8/pt active IP Right Grant
- 2009-11-24 AU AU2009325117A patent/AU2009325117C1/en active Active
- 2009-11-24 US US13/131,203 patent/US20110224262A1/en not_active Abandoned
- 2009-11-24 EP EP17183750.3A patent/EP3342767B1/en active Active
- 2009-11-24 KR KR1020117014566A patent/KR101707247B1/ko active Active
- 2009-11-24 MX MX2011005577A patent/MX2011005577A/es active IP Right Grant
- 2009-11-24 SG SG2011037926A patent/SG171413A1/en unknown
- 2009-11-24 EP EP09768563A patent/EP2367797A1/en not_active Withdrawn
- 2009-11-24 WO PCT/US2009/006251 patent/WO2010068242A1/en not_active Ceased
- 2009-11-24 EA EA201100846A patent/EA022799B1/ru not_active IP Right Cessation
- 2009-11-24 CN CN200980155333.9A patent/CN102292321B/zh active Active
- 2009-11-24 CA CA2744124A patent/CA2744124C/en active Active
- 2009-11-24 JP JP2011538598A patent/JP5603343B2/ja active Active
-
2011
- 2011-05-17 IL IL212966A patent/IL212966A/en active IP Right Grant
- 2011-05-24 ZA ZA2011/03813A patent/ZA201103813B/en unknown
-
2013
- 2013-07-03 US US13/934,439 patent/US9012478B2/en active Active
-
2015
- 2015-03-16 US US14/659,293 patent/US9663500B2/en active Active
-
2017
- 2017-04-13 US US15/486,600 patent/US10214518B2/en active Active
-
2018
- 2018-11-06 US US16/181,457 patent/US10689372B2/en active Active
-
2020
- 2020-04-30 US US16/863,625 patent/US11098034B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212966A0 (en) | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto | |
| IL207873A0 (en) | Modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto | |
| PL2370413T3 (pl) | Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych | |
| PL2364142T3 (pl) | Kompozycje modulatora receptora 5-HT<sub>2A</sub> serotoniny przydatne do leczenia związanych z nim zaburzeń | |
| PL2356101T3 (pl) | Pochodne pirymidyno- i triazyno-sulfonamidu jako B1 receptor bradykininy (B1R) Inhibitory do leczenia bólu | |
| ZA201007325B (en) | Azaindole compounds for treatment of central nervous system disorders | |
| ZA201104838B (en) | Imidazopyridine derivatives which inhibit the secretion of gastric acid | |
| IL179609A0 (en) | Imidazole variants as modulators of gaba receptor for the treatment of gi disorders | |
| ZA201000012B (en) | Use of tetramic acid derivatives for controlling viruliferous vectors | |
| IL211931A0 (en) | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides | |
| ZA201007361B (en) | (pyrazolyl carbonyl)imidazolidinone derivatives for the treatment of retroviral diseases | |
| IL201899A0 (en) | Spiro compounds for treatment of inflammatory disorders | |
| IL209417A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders | |
| IL209418A0 (en) | Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumours | |
| ZA201104663B (en) | Sulfonamide compounds for the treatment of respiratory disorders | |
| HK1162495A (en) | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto | |
| EP2240024A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| HK1145271A (en) | Compounds for the treatment of metabolic disorders | |
| HK1163684A (en) | Compounds for the treatment of metabolic disorders | |
| HK1164882A (en) | Compounds for the treatment of metabolic disorders | |
| HK1163686A (en) | Compounds for the treatment of metabolic disorders | |
| HU0900722D0 (en) | Compounds for the treatment of neurological disorders | |
| HK1150010A (en) | Synthesis of resorcylic acid lactones useful as therapeutic agents |